Analyzing...
Loading company...
Metropolis Healthcare Ltd. owns and operates medical laboratories. The company is headquartered in Gurgaon, Haryana and currently employs 4,289 full-time employees. The company went IPO on 2019-04-15. The firm offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and monitoring of the disease. The firm also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The firm offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company owns a chain of diagnostic centers across India, South Asia, Africa and the Middle East. The firm has spread its footprint across 20 Indian states and over 210 cities.
No significant concerns identified
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹1,646 Cr service revenue.
Employee costs at 22.9% of revenue — primary cost driver.
“we remain confident of delivering on our guidance of 12 to 13% organic growth rate and expanded margins for f y twenty six”
“group revenues growing 26% year on year and nine month revenues increasing by 24%”
“EBITDA margin stood at 25%, an”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.6%▲ | 9.0% |
| ROCE | 15.7%▲ | 10.4% |
| Net Margin | 11.4%▲ | 8.5% |
| EBITDA Margin | 25.0%▲ | 20.6% |
| Debt To Equity | 0.01x▼ | 0.16x |
| Rev Growth 3yr | 12.8%▼ | 14.4% |
| EPS Growth 3yr | 9.5%▼ | 9.9% |
| Employee Cost Ratio | 22.90x | - |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,646 Cr +23.6% | ₹1,331 Cr +10.2% | ₹1,208 Cr +5.2% | ₹1,148 Cr -6.5% | ₹1,228 Cr +23.1% | ₹998 Cr +16.5% | ₹856 Cr +12.5% | ₹761 Cr |
| Other Income | ₹26 Cr +69.3% | ₹15 Cr +65.8% | ₹9 Cr -40.1% | ₹15 Cr -13.6% | ₹18 Cr +46.3% | ₹12 Cr +40.6% | ₹9 Cr +4.3% | ₹8 Cr |
| Total Income | ₹1,671 Cr +24.1% | ₹1,346 Cr +10.6% | ₹1,217 Cr +4.6% | ₹1,163 Cr -6.6% | ₹1,246 Cr +23.4% | ₹1,010 Cr +16.8% | ₹865 Cr +12.4% | ₹769 Cr |
| COGS | ₹325 Cr +20.8% | ₹269 Cr +10.8% | ₹243 Cr -4.2% | ₹253 Cr -8.2% | ₹276 Cr +9.5% | ₹252 Cr +23.5% | ₹204 Cr +17.7% | ₹174 Cr |
| ₹1,403 Cr +21.4% | ₹1,155 Cr +10.9% | ₹1,042 Cr +6.8% | ₹976 Cr +0.8% | ₹969 Cr +26.5% | ₹766 Cr +14.1% | ₹671 Cr +15.4% | ₹581 Cr | |
| Profit Before Tax | ₹259 Cr +35.8% | ₹191 Cr +9.3% | ₹175 Cr -6.8% | ₹188 Cr -36.1% | ₹293 Cr +20.1% | ₹244 Cr +44.4% | ₹169 Cr -9.3% | ₹187 Cr |
| Exceptional Items | (₹9 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹16 Cr | ₹0.00 Cr +100.0% | (₹25 Cr) | (₹1 Cr) |
| ₹68 Cr +50.0% | ₹45 Cr -1.9% | ₹46 Cr +4.8% | ₹44 Cr -43.9% | ₹79 Cr +29.0% | ₹61 Cr +48.1% | ₹41 Cr -34.6% | ₹63 Cr | |
| Net Profit | ₹191 Cr +31.4% | ₹146 Cr +13.3% | ₹128 Cr -10.4% | ₹143 Cr -33.2% | ₹215 Cr +17.1% | ₹183 Cr +43.7% | ₹128 Cr +3.2% | ₹124 Cr |
| Profit (Owners) | ₹190 Cr +31.1% | ₹145 Cr +13.4% | ₹128 Cr -10.5% | ₹143 Cr -33.3% | ₹214 Cr +17.0% | ₹183 Cr +43.8% | ₹127 Cr +6.0% | ₹120 Cr |
| Minority Interest | ₹1 Cr +113.5% | ₹0.55 Cr -14.7% | ₹0.64 Cr +25.0% | ₹0.51 Cr +1.5% | ₹0.50 Cr +98.7% | ₹0.25 Cr +11.9% | ₹0.23 Cr -93.5% | ₹3 Cr |
| Other Comprehensive Income | ₹5 Cr ↑ Recovery | (₹0.31 Cr) +62.0% | (₹0.82 Cr) -136.3% | (₹0.35 Cr) +85.0% | (₹2 Cr) -114.5% | (₹1 Cr) +64.0% | (₹3 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹9.17 | ₹7.00 | ₹6.24 | ₹6.98 | ₹10.46 | ₹8.95 | ₹6.29 | ₹5.99 |
| Diluted Shares | ₹21 Cr | ₹21 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Metropolis Healthcare Limited has informed the Exchange about Schedule of Q1FY27 earnings conference call (i.e. post earnings/quarterly call), organized by JM Financial Institutional Securities Limite...
Metropolis Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Metropolis Healthcare Limited has informed the Exchange about the Letter to Shareholders containing weblink of Annual Report for the financial year 2025-26 and 26th Annual General Meeting
Metropolis Healthcare Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the financial year 2025-26'.
Metropolis Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 18, 2026
Metropolis Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Metropolis Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Metropolis Healthcare Limited has informed the Exchange about Link of Recording
Metropolis Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Metropolis Healthcare Limited has informed the Exchange regarding 'General Update'.
Metropolis Healthcare Limited has informed the Exchange about Grant of Stock Benefits
Metropolis Healthcare Limited has informed the Exchange regarding Allotment of 4,200 Equity Shares under the Metropolis-Restrictive Stock Unit Plan, 2020
Metropolis Healthcare Limited has informed the Exchange about meeting with investors scheduled on May 27, 2026
Metropolis Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Metropolis Healthcare Limited has informed the Exchange regarding allotment of 15,54,95,826 equity shares pursuant to Bonus on March 23, 2026